Specialty Pharmacy

The report projects changes in upcoming health care markets, including kidney care, digital health, drug cost transparency, the loneliness epidemic, and the self-care market.

The findings support the inclusion of these patient populations in ICI-based clinical trials and treatment.

Safety net providers, which historically work in underserved communities, have successfully petitioned state legislatures to take action on 340B 2-tier pricing.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

Top news of the day from across the health care landscape.

The ErbB inhibitors, gefitinib, erbstatin, and tryphostin AG825, inhibit a cell signaling process controlling the death-rate of neutrophils, immune cells, which cause damage to the lungs.

The app takes the authoritative, evidence-based 2015 World Health Organization pre-exposure prophylaxis guidelines and adapts for a mobile device.

Dawn Hershman, MD, MS, offers some potential treatments for aromatase inhibitor-caused arthralgia in breast cancer patients. This video was filmed at the 2019 San Antonio Breast Cancer Symposium.

Tofacitinib, currently used to treat rheumatoid arthritis and ulcerative colitis, has a correcting effect on defects that occur in inflammation.

Top news of the day from across the health care landscape.

Belantamab mafodotin has the potential for durable responses in patients with multiple myeloma whose disease has relapsed or is resistant to standard therapies.

Top news of the day from across the health care landscape.

Because of the vulnerabilities of CDK4/6i-resistant tumors, researchers believe that it is imperative to improve the survival of this group of patients.

Two studies linked ozone levels and wood burning as a source of heat to an increased risk of developing chronic obstructive pulmonary disease.

Rita Nanda, MD, discusses various immunotherapy drugs in the pipeline and which she thinks will be approved next. This video was filmed December 11 at the 2019 San Antonio Breast Cancer Symposium.

The rise in value-based reimbursement models has required oncology care providers to assume an unprecedented level of accountability.

The decline in the cancer mortality rate attributed to immunotherapy methods, early detection, and treatment.

Top news of the day from across the health care landscape.

After injecting the flu vaccine into a tumor cell, researchers found that the injection either slowed the growth or shrunk the tumor itself.

The diazepam nasal spray was granted 7 years of Orphan Drug Exclusivity by the FDA Office of Orphan Products Development.

The Supreme Court released their decision to review Rutledge v. Pharmaceutical Care Management Association, which could affect pharmacy benefits across the country.

Through the Ready, Set, PrEP program, qualified patients from across the United States can access PrEP medication for the prevention of HIV, for free.

Top news of the day from across the health care landscape.

Top news of the week from Specialty Pharmacy Times.

This medication is the first precision therapy approved to treat a genomically defined population of patients with GIST, according to Blueprint Medicines.

Top news of the day from across the health care landscape.

Micafungin injection is the first antifungal drug approved in the United States specifically for pediatric patients younger than 4 years of age with invasive candidiasis.

Secukinumab provided early and sustained resolution of enthesitis in patients with psoriatic arthritis based on post hoc analysis pooled data from the FUTURE trial.

Officials with the FDA have approved pembrolizumab (Keytruda, Merck) for the treatment of certain patients with Bacillus Calmette-Guerin-unresponsive, high-risk, non-muscle invasive bladder cancer.